Scopus BioPharma Inc. (SCPS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 11.71 Million USD | -57.61% |
| 2021 | 27.63 Million USD | 172.11% |
| 2020 | 10.15 Million USD | 277.55% |
| 2019 | 2.68 Million USD | 292.14% |
| 2018 | 685.96 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 2.67 Million USD | 45.96% |
| 2023 Q2 | 2.92 Million USD | 9.3% |
| 2022 FY | 11.71 Million USD | -57.61% |
| 2022 Q4 | 1.83 Million USD | -3.3% |
| 2022 Q3 | 1.89 Million USD | -42.81% |
| 2022 Q2 | 3.31 Million USD | -28.78% |
| 2022 Q1 | 4.66 Million USD | -28.5% |
| 2021 Q3 | 2.75 Million USD | -81.94% |
| 2021 FY | 27.63 Million USD | 172.11% |
| 2021 Q1 | 3.07 Million USD | 330.36% |
| 2021 Q2 | 15.28 Million USD | 397.27% |
| 2021 Q4 | 6.51 Million USD | 136.2% |
| 2020 Q4 | 714.12 Thousand USD | -18.43% |
| 2020 Q1 | 619.24 Thousand USD | -35.76% |
| 2020 Q2 | 7.94 Million USD | 1183.07% |
| 2020 FY | 10.15 Million USD | 277.55% |
| 2020 Q3 | 875.46 Thousand USD | -88.98% |
| 2019 Q4 | 963.88 Thousand USD | 20.91% |
| 2019 FY | 2.68 Million USD | 292.14% |
| 2019 Q3 | 797.22 Thousand USD | 82.35% |
| 2019 Q2 | 437.18 Thousand USD | -11.08% |
| 2019 Q1 | 491.65 Thousand USD | 0.0% |
| 2018 Q1 | 122.48 Thousand USD | 0.0% |
| 2018 Q2 | 152.22 Thousand USD | 24.28% |
| 2018 FY | 685.96 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -1671.674% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -26.401% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 60.941% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 82.553% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 26.056% |
| Better Therapeutics, Inc. | 38.26 Million USD | 69.382% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 71.209% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | 5.47% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 65.386% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 65.964% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 89.199% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -1079.973% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 64.053% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 75.049% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -864.435% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 41.247% |
| Molecular Templates, Inc. | 63.09 Million USD | 81.432% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 15.911% |
| NexImmune, Inc. | 28.16 Million USD | 58.41% |
| Orgenesis Inc. | 45.75 Million USD | 74.398% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 54.323% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -15856.845% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 27.441% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 97.097% |
| Statera Biopharma, Inc. | 28.82 Million USD | 59.365% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 38.111% |
| Trevena, Inc. | 38.41 Million USD | 69.503% |
| Vaxxinity, Inc. | 56.05 Million USD | 79.1% |
| Vaccinex, Inc. | 23.45 Million USD | 50.054% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -1018.923% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 76.891% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -61.038% |